NTRX-07

A potent and selective CB2 agonist

Immune cells, including microglia within the central nervous system, express CB2 receptors. When activated these receptors can modulate immune cell migration and cytokine release decreasing pro-inflammatory responses. For this reason, CB2 receptors have become the subject of considerable research as a potential therapeutic target to treat a host of neuro-inflammatory disorders. The ideal therapeutic candidate will have high affinity for the CB2 receptor while avoiding the adverse psychotropic effects that accompany CB1 receptor-based therapies. Furthermore, it will be able to penetrate the blood-brain barrier providing for high expression levels in the CNS.
Through a multidisciplinary medicinal approach we have developed NTRX-07 as a potent and selective CB2 receptor agonist that can be orally administered, yielding high-level CNS expression. Multiple pre-clinical studies have demonstrated that NTRX-07 promotes neuronal survival through decreasing pro-inflammatory microglial activity. Pre-clinical efficacy has been established in multiple neuropathic pain models, including chemotherapy-induced peripheral neuropathy (CIPN), nerve ligation, and complex regional pain syndrome (CRPS) induced by ischemic injury. Furthermore, NTRX-07 has been shown to improve memory loss observed in Alzheimer disease rodent models. NTRX-07 has passed all basic ADMET testing as well as genotoxicity and in-vitro cardiac safety; no in vivo toxicology or psychomimetic effects have been observed.